Dicot Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	82.4	59.06	45.03	31.67	27.13	Upgrade
Other Operating Expenses	0.2	0.21	-0	0.13	0.11	Upgrade
Operating Expenses	82.6	59.28	45.03	31.8	27.25	Upgrade
Operating Income	-82.6	-59.28	-45.03	-31.8	-27.25	Upgrade
Interest Expense	-	-0.01	-0.07	-0.03	-0	Upgrade
Interest & Investment Income	2.2	1.57	0.91	-	0	Upgrade
Currency Exchange Gain (Loss)	-	0.03	0.03	0.08	0.05	Upgrade
Other Non Operating Income (Expenses)	0.2	-	-	-	-	Upgrade
EBT Excluding Unusual Items	-80.2	-57.7	-44.16	-31.76	-27.2	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-	0.03	Upgrade
Pretax Income	-80.2	-57.7	-44.16	-31.76	-27.17	Upgrade
Net Income	-80.2	-57.7	-44.16	-31.76	-27.17	Upgrade
Net Income to Common	-80.2	-57.7	-44.16	-31.76	-27.17	Upgrade
Shares Outstanding (Basic)	1,947	1,091	530	120	64	Upgrade
Shares Outstanding (Diluted)	1,955	1,091	530	121	64	Upgrade
Shares Change (YoY)	79.20%	105.97%	336.53%	89.21%	124.32%	Upgrade
EPS (Basic)	-0.04	-0.05	-0.08	-0.26	-0.42	Upgrade
EPS (Diluted)	-0.04	-0.05	-0.08	-0.26	-0.42	Upgrade
Free Cash Flow	-85.8	-58.87	-45.23	-29.71	-25.87	Upgrade
Free Cash Flow Per Share	-0.04	-0.05	-0.09	-0.24	-0.40	Upgrade
EBITDA	-82.59	-59.27	-45.03	-31.79	-27.24	Upgrade
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01	Upgrade
EBIT	-82.6	-59.28	-45.03	-31.8	-27.25	Upgrade
Revenue as Reported	0.2	0.03	0.23	0.12	0.08	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.